Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call Transcript
08:31pm, Monday, 07'th Nov 2022
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Murphy - Manager, Investor Relations Christopher Posner - President, CE
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Cara Therapeutics (CARA) Might Surprise This Earnings Season
09:47am, Friday, 04'th Nov 2022
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cara Therapeutics to Present at Upcoming Investor Conferences
11:00am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
Cara Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 02'nd Nov 2022
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
02:00pm, Monday, 31'st Oct 2022 Zacks Investment Research
Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
11:00am, Monday, 24'th Oct 2022 GlobeNewswire Inc.
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
07:00am, Monday, 24'th Oct 2022
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High?
01:55pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
The mean of analysts' price targets for Cara (CARA) points to a 132.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
11:00am, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
11:00am, Monday, 12'th Sep 2022 GlobeNewswire Inc.
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
12:15pm, Thursday, 08'th Sep 2022 GlobeNewswire Inc.
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Tuesday, 06'th Sep 2022
STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patie
Cara Therapeutics: All Eyes On Korsuva Launch Metrics
05:03pm, Thursday, 01'st Sep 2022
Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral difelikefalin, with positive phase 2 data for NP opening
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
11:00am, Wednesday, 24'th Aug 2022 GlobeNewswire Inc.
Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP Presentation will highlight opportunity for oral dif
